year 16, Issue 6 (November - December 2022)                   Iran J Med Microbiol 2022, 16(6): 543-550 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mokhtari F, Kaboosi H, Mohebbi S R, Asadzadeh Aghdaei H, Zali M R Z. Evaluation of Circulating MicroRNA-222 in Patients with Chronic Hepatitis B virus Infection as a Potential Noninvasive Diagnostic Biomarker. Iran J Med Microbiol 2022; 16 (6) :543-550
1- Department of Microbiology, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran
2- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran ,
3- Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (2199 Views)

Background and Aim: Circulating microRNAs have the potential to serve as biomarkers in diagnostics and monitoring of disease progression, including liver diseases. Therefore, this study investigated the alteration in the expression levels of microRNA-222 (miR-222) in patients with chronic hepatitis B (CHB) as a potential diagnostic biomarker.
Materials and Methods: MiR-222 expression was analyzed in the 86 plasma samples, including 43 patients with CHB and 43 healthy individuals as a control group. RNA extraction and cDNA synthesis processes were done, and then the expression of the miR-222 was measured by qRT-PCR. The Mann-Whitney U-test Spearman analyzed the results to show the correlation between miR-222 and clinical parameters.
Results: MiR-222 had a difference in expression levels between the patient and control groups (miRNA-222 Fold change= 1.384). Nevertheless, a statically significant difference was not observed (p value=0.269).
Conclusion: Our study showed that even though changes in miR-222 expression levels in the group of patients with chronic hepatitis B compared to the healthy group, it could not be utilized as a precise diagnostic biomarker, and more studies, on a broader scale, are needed to determine the role of this microRNA in patients with CHB.

Full-Text [PDF 538 kb]   (531 Downloads) |   |   Full-Text (HTML)  (586 Views)  
Type of Study: Original Research Article | Subject: Medical Virology
Received: 2022/05/19 | Accepted: 2022/07/3 | ePublished: 2022/09/9

1. Seto W-K, Lo Y-R, Pawlotsky J-M, Yuen M-F. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313-24. [DOI:10.1016/S0140-6736(18)31865-8]
2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55. [DOI:10.1016/S0140-6736(15)61412-X]
3. Organization WH. Preventing perinatal hepatitis B virus transmission: a guide for introducing and strengthening hepatitis B birth dose vaccination. 2015.
4. Liver EAFTSOT. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. [DOI:10.1016/j.jhep.2017.03.021] [PMID]
5. Geier DA, Geier DA, Geier MR, Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005;38(4):295-301. [DOI:10.1080/08916930500144484] [PMID]
6. Russo FP, Zanetto A, Pinto E, Battistella S, Penzo B, Burra P, et al. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int J Mo Sci. 2022;23(1):500. [DOI:10.3390/ijms23010500] [PMID] [PMCID]
7. Guvenir M, Arikan A. Hepatitis B virus: from diagnosis to treatment. Pol J Microbiol. 2020;69(4):391. [DOI:10.33073/pjm-2020-044] [PMID] [PMCID]
8. Liu L, Nie Y, Zhang Y, Liu Q, Zhu X. Liver Stiffness Is a Predictor of Rebleeding in Patients With Hepatitis B-Related Cirrhosis: A Real-World Cohort Study. Front Med. 2021:1134. [DOI:10.3389/fmed.2021.690825] [PMID] [PMCID]
9. Volovat SR, Volovat C, Hordila I, Hordila D-A, Mirestean CC, Miron OT, et al. MiRNA and LncRNA as potential biomarkers in triple-negative breast cancer: a review. Front Oncol. 2020:2423. [DOI:10.3389/fonc.2020.526850] [PMID] [PMCID]
10. Nagata S, Tanaka M. Programmed cell death and the immune system. Nat Rev Immunol. 2017;17(5):333-40. [DOI:10.1038/nri.2016.153] [PMID]
11. Su Z, Yang Z, Xu Y, Chen Y, Yu Q. MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget. 2015;6(11):8474. [DOI:10.18632/oncotarget.3523] [PMID] [PMCID]
12. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci. 2002;99(24):15524-9. [DOI:10.1073/pnas.242606799] [PMID] [PMCID]
13. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753-6. [DOI:10.1158/0008-5472.CAN-04-0637] [PMID]
14. Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem. 2007;282(4):2130-4. [DOI:10.1074/jbc.C600252200] [PMID]
15. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006;130(7):2113-29. [DOI:10.1053/j.gastro.2006.02.057] [PMID]
16. Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 2005;309(5740):1573-6. [DOI:10.1126/science.1115079] [PMID]
17. Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):1-9. [DOI:10.1038/s41598-018-27521-y] [PMID] [PMCID]
18. Li Y, Di C, Li W, Cai W, Tan X, Xu L, et al. Oncomirs miRNA-221/222 and tumor suppressors miRNA-199a/195 are crucial miRNAs in liver cancer: a systematic analysis. Dig Dis Sci. 2016;61(8):2315-27. [DOI:10.1007/s10620-016-4156-8] [PMID] [PMCID]
19. Han T-S, Ban HS, Hur K, Cho H-S. The epigenetic regulation of HCC metastasis. Int J Mol Sci. 2018;19(12):3978. [DOI:10.3390/ijms19123978] [PMID] [PMCID]
20. Wang X, Gao J, Zhou B, Xie J, Zhou G, Chen Y. Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles. Life Sci. 2019;232:116596. [DOI:10.1016/j.lfs.2019.116596] [PMID]
21. Zhang Z-Z, Liu X, Wang D-Q, Teng M-K, Niu L-W, Huang A-L, et al. Hepatitis B virus and hepatocellular carcinoma at the miRNA level. World J Gastroenterol: WJG. 2011;17(28):3353. [DOI:10.3748/wjg.v17.i28.3353] [PMID] [PMCID]
22. Li D, Zhang J, Li J. Role of miRNA sponges in hepatocellular carcinoma. Clinica chimica acta. 2020;500:10-9. [DOI:10.1016/j.cca.2019.09.013] [PMID]
23. Yerukala Sathipati S, Ho S-Y. Novel miRNA signature for predicting the stage of hepatocellular carcinoma. Sci Rep. 2020;10(1):1-12. [DOI:10.1038/s41598-020-71324-z] [PMID] [PMCID]
24. Qin S, Xu J, Yi Y, Jiang S, Jin P, Xia X, et al. Transcription factors and methylation drive prognostic miRNA dysregulation in hepatocellular carcinoma. Front Oncol. 2021;11. [DOI:10.3389/fonc.2021.691115] [PMID] [PMCID]
25. Rashad NM, El-Shal AS, Shalaby SM, Mohamed SY. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma. Mol Cell Biochem. 2018;447(1):125-36. [DOI:10.1007/s11010-018-3298-8] [PMID]
26. Ji J, Chen H, Liu X-P, Wang Y-H, Luo C-L, Zhang W-W, et al. A miRNA combination as promising biomarker for hepatocellular carcinoma diagnosis: a study based on bioinformatics analysis. J Cancer. 2018;9(19):3435. [DOI:10.7150/jca.26101] [PMID] [PMCID]
27. Świtlik WZ, Bielecka-Kowalska A, Karbownik MS, Kordek R, Jabłkowski M, Szemraj J. Forms of diagnostic material as sources of miRNA biomarkers in hepatocellular carcinoma: a preliminary study. Biomark Med. 2019;13(07):523-34. [DOI:10.2217/bmm-2018-0485] [PMID]
28. Pratedrat P, Chuaypen N, Nimsamer P, Payungporn S, Pinjaroen N, Sirichindakul B, et al. Diagnostic and prognostic roles of circulating miRNA-223-3p in hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2020;15(4):e0232211. [DOI:10.1371/journal.pone.0232211] [PMID] [PMCID]
29. Sartorius K, Makarova J, Sartorius B, An P, Winkler C, Chuturgoon A, et al. The regulatory role of microRNA in hepatitis-B virus-associated hepatocellular carcinoma (HBV-HCC) pathogenesis. Cells. 2019;8(12):1504. [DOI:10.3390/cells8121504] [PMID] [PMCID]
30. Zhang S, Chen L, Wang Y, Tang W, Chen Y, Liu L. Investigation of the Association of miRNA-499, miRNA-146a, miRNA-196a2 Loci with Hepatocellular Carcinoma Risk: A Case-Control Study Involving 1507 Subjects. DNA Cell Biol. 2020;39(3):379-88. [DOI:10.1089/dna.2019.5145] [PMID]
31. Li F, Wang F, Zhu C, Wei Q, Zhang T, Zhou YL. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker. Int J Nanomedicine. 2018;13:2295. [DOI:10.2147/IJN.S157805] [PMID] [PMCID]
32. Kholodenko IV, Yarygin KN. Cellular mechanisms of liver regeneration and cell-based therapies of liver diseases. Biomed Res Int. 2017;2017. [DOI:10.1155/2017/8910821] [PMID] [PMCID]
33. Tao J, Jiang L, Chen X. Roles of microRNA in liver cancer. Liver Res. 2018;2(2):61-72. [DOI:10.1016/j.livres.2018.06.002]
34. Chen Y, Gao D-Y, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128-41. [DOI:10.1016/j.addr.2014.05.009] [PMID] [PMCID]
35. McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 2011;226(11):2762-81. [DOI:10.1002/jcp.22647] [PMID]
36. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227-30. [DOI:10.1001/archinte.160.21.3227] [PMID]
37. Contreras-Zentella ML, Hernández-Muñoz R. Is liver enzyme release really associated with cell necrosis induced by oxidant stress? Oxid Med Cell Longev. 2016;2016. [DOI:10.1155/2016/3529149] [PMID] [PMCID]
38. Fadhil RS, Nair RG, Nikolarakos D, Wei MQ. Next generation sequencing identifies novel diagnostic biomarkers for head and neck cancers. Oral Cancer. 2019;3(3):69-78. [DOI:10.1007/s41548-019-00019-5]
39. Moxon S, Jing R, Szittya G, Schwach F, Pilcher RLR, Moulton V, et al. Deep sequencing of tomato short RNAs identifies microRNAs targeting genes involved in fruit ripening. Genome Res. 2008;18(10):1602-9. [DOI:10.1101/gr.080127.108] [PMID] [PMCID]
40. Musaddaq G, Shahzad N, Ashraf MA, Arshad MI. Circulating liver-specific microRNAs as noninvasive diagnostic biomarkers of hepatic diseases in human. Biomarkers. 2019;24(2):103-9. [DOI:10.1080/1354750X.2018.1528631] [PMID]
41. Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81:75-93. [DOI:10.1016/j.addr.2014.09.001] [PMID]
42. Singh R, Ramasubramanian B, Kanji S, Chakraborty AR, Haque SJ, Chakravarti A. Circulating microRNAs in cancer: Hope or hype? Cancer Lett. 2016;381(1):113-21. [DOI:10.1016/j.canlet.2016.07.002] [PMID]
43. Wang B, Howel P, Bruheim S, Ju J, Owen LB, Fodstad O, et al. Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array. PloS One. 2011;6(2):e17167. [DOI:10.1371/journal.pone.0017167] [PMID] [PMCID]
44. Pirola CJ, Gianotti TF, Castaño GO, Mallardi P, San Martino J, Ledesma MMGL, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800-12. [DOI:10.1136/gutjnl-2014-306996] [PMID] [PMCID]
45. Mokhtari F, Mohebbi SR, Sharifian A, Ramandi M, Razzaghi MR. Circulating non-coding RNAs as potential diagnostic biomarkers in liver diseases. Gastroenterol Hepatol Bed Bench. 2021;14(Suppl1):S10.
46. Shah MY, Calin GA. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med. 2011;3(8):1-4. [DOI:10.1186/gm272] [PMID] [PMCID]
47. Motawi TM, Sadik NA, Shaker OG, Ghaleb MH. Elevated serum microRNA-122/222 levels are potential diagnostic biomarkers in Egyptian patients with chronic hepatitis C but not hepatic cancer. Tumor Biology. 2016;37(7):9865-74. [DOI:10.1007/s13277-016-4884-6] [PMID]
48. Xu J, An P, Winkler CA, Yu Y. Dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma: potential as biomarkers and therapeutic targets. Front Oncol. 2020:1271. [DOI:10.3389/fonc.2020.01271] [PMID] [PMCID]
49. Qi P, Cheng S-q, Wang H, Li N, Chen Y-f, Gao C-f. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PloS One. 2011;6(12):e28486. [DOI:10.1371/journal.pone.0028486] [PMID] [PMCID]
50. Ladeiro Y, Couchy G, Balabaud C, Bioulac‐Sage P, Pelletier L, Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008;47(6):1955-63. [DOI:10.1002/hep.22256] [PMID]
51. Li W, Xie L, He X, Li J, Tu K, Wei L, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer. 2008;123(7):1616-22. [DOI:10.1002/ijc.23693] [PMID]
52. Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol. 2016;16(5):279-94. [DOI:10.1038/nri.2016.40] [PMID]
53. Bandopadhyay M, Banerjee A, Sarkar N, Panigrahi R, Datta S, Pal A, et al. Tumor suppressor micro RNA miR-145 and onco micro RNAs miR-21 and miR-222 expressions are differentially modulated by hepatitis B virus X protein in malignant hepatocytes. BMC cancer. 2014;14(1):1-12. [DOI:10.1186/1471-2407-14-721] [PMID] [PMCID]
54. Sasaki R, Osaki M, Okada F. MicroRNA-based diagnosis and treatment of metastatic human osteosarcoma. Cancers. 2019;11(4):553. [DOI:10.3390/cancers11040553] [PMID] [PMCID]
55. Cheng Y, Du L, Shi Q, Jiao H, Zhang X, Hao Y, et al. Identification of miR-221 and -222 as important regulators in genotype IV swine hepatitis E virus ORF3-expressing HEK 293 cells. Virus Genes. 2013;47(1):49-55. [DOI:10.1007/s11262-013-0912-4] [PMID]
56. Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut. 2012;61(11):1600-9. [DOI:10.1136/gutjnl-2011-300717] [PMID]
57. Yang F, Wang Y, Xue J, Cai X, Luo L, Wu H-K, et al. Immune clearance-associated microRNAs in circulating Microvesicles from chronic hepatitis B patients. Int J Clin Exp Med. 2018;11(10):10475-86. [DOI:10.1186/s13148-018-0492-1] [PMID] [PMCID]
58. Sohn W, Kim J, Kang SH, Yang SR, Cho J-Y, Cho HC, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med. 2015;47(9):e184-e. [DOI:10.1038/emm.2015.68] [PMID] [PMCID]
59. Wong QWL, Lung RWM, Law PTY, Lai PBS, Chan KYY, To KF, et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology. 2008;135(1):257-69. [DOI:10.1053/j.gastro.2008.04.003] [PMID]
60. Lendvai G, Szekerczés T, Gyöngyösi B, Schlachter K, Kontsek E, Pesti A, et al. MicroRNA expression in focal nodular hyperplasia in comparison with cirrhosis and hepatocellular carcinoma. Pathol Oncol Res. 2019;25(3):1103-9. [DOI:10.1007/s12253-018-0528-z] [PMID]
61. Yang Y-F, Wang F, Xiao J-J, Song Y, Zhao Y-Y, Cao Y, et al. MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27. Int J Clin Exp Med. 2014;7(4):893.
62. Zhang X, Daucher M, Armistead D, Russell R, Kottilil S. MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-α. PloS One. 2013;8(2):e55733. [DOI:10.1371/journal.pone.0055733] [PMID] [PMCID]
63. Simão ADL. Role of mitochondria-targeting miRNAs in non-alcoholic fatty liver disease. 2019.
64. PingYing L, YongGeng Y, LunGen L, ZhiYong Z, YaPing W, YingCai M. Value of microRNAs in diagnosis of chronic hepatitis B-related liver fibrosis. J Clin Hepatol. 2017;33(12):2412-5.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Medical Microbiology

Designed & Developed by : Yektaweb | Publisher: Farname Inc